Diagnosis: Bleomycin-induced flagellate pigmentation
A 65-year-old male presented with linear, whip-like hyperpigmented streaks on his back following treatment with bleomycin for squamous cell carcinoma. The pigmentation developed after several doses of bleomycin and was characterized by distinct linear patterns resembling flagella. This case highlights a rare but notable cutaneous reaction to bleomycin, prompting consideration of the differential diagnoses for drug-induced skin changes.
A 65-year-old male with a history of squamous cell carcinoma treated with bleomycin presented with linear, whip-like hyperpigmented streaks on his back for three weeks. Examination revealed distinct, hyperpigmented streaks that were asymptomatic and aligned with the distribution of the bleomycin injections.Location: Back, extending along the injection sites.Pattern: Linear, whip-like streaks.Color: Dark brown to black pigmentation.Symptomatology: Asymptomatic; no pruritus or pain.Duration: Noted three weeks post-therapy.
The patient underwent bleomycin therapy for squamous cell carcinoma, with the onset of pigmentation occurring approximately three weeks after the initial treatment. He reported no prior history of similar skin changes and had no known allergies. He has a history of smoking and a family history of skin cancer. The patient denied any recent changes in medication or exposures to other potential irritants.Onset: Three weeks post-bleomycin treatment.Prior Treatments: None for similar skin changes.Medical History: Squamous cell carcinoma, hypertension.Family History: Skin cancer in a sibling.Social History: Former smoker, no current tobacco use.
Acute / First-Line ManagementReassurance regarding the benign nature of the pigmentation.Topical emollients to maintain skin hydration.Consideration of topical corticosteroids for any associated inflammation.Workup and Diagnostic ConfirmationClinical examination to assess the distribution and characteristics of the pigmentation.Consideration of a skin biopsy if there is uncertainty in diagnosis or if the lesions appear atypical.Long-Term ManagementRegular follow-up to monitor for any changes in pigmentation.Education regarding sun protection to prevent further skin damage.Consideration of cosmetic options for patients desiring treatment for persistent pigmentation.
Drug-induced pigmentation: Includes various medications leading to hyperpigmentation; distinguishing factors include the timing of onset and specific drug history.Idiopathic guttate hypomelanosis: Typically presents as small white spots in sun-exposed areas, more common in older adults, without preceding drug exposure.Post-inflammatory hyperpigmentation: Results from skin injury or inflammation; however, the linear pattern is less typical.Lichen planus pigmentosus: Characterized by reticular pigmentation, often on sun-exposed areas; associated pruritus can help differentiate.Dermatopathic lymphadenopathy: May present with similar pigmentation but usually has systemic signs such as lymphadenopathy.Melasma: Common in women, often triggered by sun exposure and hormonal changes; however, the pattern is usually more diffuse.Chloasma: Similar to melasma, but typically associated with pregnancy or hormonal therapy; distribution differs.Other drug reactions: Various other drugs can cause pigmentation changes; thorough medication history is essential.
High-Yield PearlsBleomycin: Known to cause unique cutaneous reactions, including flagellate pigmentation, particularly after multiple doses.Pattern recognition: Understanding the distinctive linear pattern of pigmentation is crucial for diagnosis.Reassurance: Most cases of drug-induced pigmentation are benign and self-limiting, requiring minimal intervention.Patient education: Important to inform patients about potential skin changes associated with therapies.Monitoring: Regular follow-up is essential to differentiate between benign changes and potential malignancies.Recognizing drug-induced skin changes can prevent unnecessary anxiety and interventions in patients.
Tags: bleomycin, flagellate, drug pigmentation